Sunovion announces new Phase 3 trial
Sunovion Pharmaceuticals of Marlborough announced the start of a phase 3 clinical trial program for SUN-101, an inhalation solution being investigated for the treatment of chronic obstructive pulmonary disease (COPD).
The solution is delivered through the company’s investigational eFlow nebulizer system, and is being evaluated as a twice-daily maintenance treatment for patients suffering from bronchoconstriction due to COPD.
The SUN-101/eFlow Phase 3 clinical trial program includes three studies currently enrolling about 2,340 adults with moderate to severe COPD.
“We are committed to bringing innovative medications to patients with COPD and recognize the importance of developing (a treatment) that can be delivered via a convenient and easy-to-use nebulizer,” said Dr. Antony Loebel, chief medical officer at Sunovion, who added that “there is a high prevalence of undertreated COPD patients that could benefit from new nebulized treatment options.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments